| __timestamp | Dynavax Technologies Corporation | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 17986000 |
| Thursday, January 1, 2015 | 22180000 | 32480000 |
| Friday, January 1, 2016 | 37257000 | 68081000 |
| Sunday, January 1, 2017 | 27367000 | 169906000 |
| Monday, January 1, 2018 | 64770000 | 248932000 |
| Tuesday, January 1, 2019 | 74986000 | 354100000 |
| Wednesday, January 1, 2020 | 79256000 | 433300000 |
| Friday, January 1, 2021 | 100156000 | 583300000 |
| Saturday, January 1, 2022 | 131408000 | 752700000 |
| Sunday, January 1, 2023 | 152946000 | 887600000 |
| Monday, January 1, 2024 | 1007200000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, managing operational expenses is crucial for sustained growth. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation from 2014 to 2023. Over this period, Neurocrine Biosciences has consistently outpaced Dynavax in SG&A spending, with a notable increase of over 4,800% from 2014 to 2023. In contrast, Dynavax's SG&A expenses grew by approximately 760% during the same period. This disparity highlights Neurocrine's aggressive investment in administrative and sales functions, potentially fueling its market expansion. Meanwhile, Dynavax's more conservative approach may reflect a focus on cost efficiency. As both companies navigate the evolving biotech landscape, their SG&A strategies will likely play a pivotal role in shaping their competitive positions.
Who Optimizes SG&A Costs Better? Sanofi or Neurocrine Biosciences, Inc.
SG&A Efficiency Analysis: Comparing Sanofi and Dynavax Technologies Corporation
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc.
argenx SE and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Neurocrine Biosciences, Inc.
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Catalent, Inc. Trends and Insights
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: SG&A Expense Trends
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. and Mesoblast Limited: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Novavax, Inc.
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Dynavax Technologies Corporation
Breaking Down SG&A Expenses: Protagonist Therapeutics, Inc. vs Dynavax Technologies Corporation